SCHEMBL1360201

SCHEMBL1360201

CC1CC(=O)CCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10261526 1.00
SCHEMBL10261945 1.00
Hydrochloric Acid SCHEMBL22999867 0.97
Hydrochloric Acid SCHEMBL9951227 0.97
Hydrochloric Acid SCHEMBL4510205 0.97
Acetic Acid SCHEMBL431606 0.89 CRBN (0.33)
Acetic Acid SCHEMBL15769363 0.89 CRBN (0.33)
Acetic Acid SCHEMBL15769581 0.89 CRBN (0.33)
SCHEMBL6582866 0.85
Hydrochloric Acid SCHEMBL26675905 0.83 TRIM24 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112543676-B Catalyst with addition of alkyl lactate, preparation thereof and use thereof in hydrotreating and/or hydrocracking process IFP 新能源公司 2024-03-01 CN claimed
US-20250320196-A1 APOL1 INHIBITORS AND METHODS OF USES THEREOF MAZE THERAPEUTICS INC (US) 2025-10-16 US disclosed
US-20250136620-A1 BTK DEGRADER NEWAVE PHARMACEUTICAL INC. 2025-05-01 US disclosed
US-12281060-B2 Remodilins for airway remodeling and organ fibrosis THE UNIVERSITY OF CHICAGO (US) 2025-04-22 US disclosed
US-20240415851-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA THE UNIVERSITY OF CHICAGO (US) 2024-12-19 US disclosed
WO-2024208225-A1 DIHYDROTHIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 上海壹迪生物技术有限公司 2024-10-10 WO disclosed
CN-113301995-B Method for reactivating a catalyst for a hydrotreating and/or hydrocracking process IFP 新能源公司 2024-03-29 CN disclosed
CN-113412156-B Method for reactivating non-regenerated spent catalyst from a gasoline hydrodesulfurization process IFP 新能源公司 2024-03-01 CN disclosed
US-20240018138-A1 PYRIDO[4,3-b]INDOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS VENTUS THERAPEUTICS U.S., INC. 2024-01-18 US disclosed
US-20230339936-A1 COMPOUND HAVING KINASE INHIBITORY ACTIVITY CYTOSINLAB THERAPEUTICS CO., LTD. (CN) 2023-10-26 US disclosed
EP-1204659-A2 SEROTONERGIC BENZOFURANS ELI LILLY AND COMPANY (US) 2002-05-15 EP disclosed
WO-2001087881-A1 PIPERIDYINDOLES AS SEROTONIN RECEPTOR LIGANDS ELI LILLY AND COMPANY (US) 2001-11-22 WO disclosed
WO-2001009126-A1 SEROTONERGIC BENZOTHIOPHENES ELI LILLY AND COMPANY (US) 2001-02-08 WO disclosed
WO-2001009122-A2 SEROTONERGIC BENZOFURANS ELI LILLY AND COMPANY (US) 2001-02-08 WO disclosed
US-6096763-A ADMINISTERING TO THE PATIENTS A2-OXO-1-BENZIMIDAZOLINYL)PIPERIDIN-1-YL)ALKYL)-1,2BENZISOTHIA ZOL-3-(2H)-ONE DERIVATIVE AS ALPHA-1A ADRENERGIC RECEPTOR ANTAGONIST MERCK & CO., INC. (US) 2000-08-01 US disclosed
US-5952351-A DERIVATIVES OF 1,1,3-TRIOXO-2-((2-OXOBENZIMIDAZOLIN- OR BENZOXAZOLIN-2-YL)-PIPERIDIN-4,1-YLENE-)-1,2-BENZISOTHIAZOLE; TREATMENT OF BENIGN PROSTATIC HYPERPLASIA; SELECTIVE RELAXATION OF SMOOTH MUSCLE WITHOUT INDUCING HYPOTENSION MERCK & CO., INC. (US) 1999-09-14 US disclosed
EP-0812196-A4 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO INC (US) 1998-05-20 EP disclosed
EP-0812196-A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1997-12-17 EP disclosed
WO-1997016192-A1 MUSCARINE ANTAGONISTS MERCK & CO., INC. (US) 1997-05-09 WO disclosed
WO-1996025934-A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1996-08-29 WO disclosed